Europe Sodium Hyaluronate Market Size was $535.27 million in 2023

Europe Sodium Hyaluronate Market Overview

According to Global Market Monitor, the Europe sodium hyaluronate market size was $535.27 million in 2023 with a CAGR of 4.89% from 2023 to 2029.

Sodium hyaluronate is the naturally occurring and widespread component found within the extracellular matrix (ECM) within bodily tissues, especially those of the face. Sodium hyaluronate is a polysaccharide of linear and repeating structural Tons, and it is the sodium salt of the hyaluronic acid.

Sodium hyaluronate has played an important role in the application prospects of the medical, medical beauty, and cosmetics industries. Because of its water-binding and water-attracting attributes, sodium hyaluronate performs well in smoother, softer skin with decreased wrinkles and an all-around fuller appearance.The popularity of Sodium Hyaluronate products among young people drives the growth of the Sodium Hyaluronate market. Although the effect is temporary, it is still popular among young people for Sodium Hyaluronate injection. It is also widely used in skin care products and cosmetics.

Side effects of Sodium Hyaluronate

There are some allergic reactions and side effects after having Sodium Hyaluronate. Common side effects may include warmth, pain, redness, stiffness, bruising, or puffiness where the medicine was injected; nausea, stomach pain; trouble walking; swelling in your hands or feet; back pain, joint pain, muscle pain; numbness or tingly feeling; headache, dizziness; or runny or stuffy nose, sneezing, sore throat. Besides, when used in ophthalmological procedures, sodium hyaluronate may cause postoperative inflammation, corneal edema or decompensation, and short-term increases in intraocular pressure.

Galderma (Nestlé) is one of the major players operating in the Sodium Hyaluronate market, holding a share of 12.3% in 2023. It researches, develops, manufactures, and supplies dermatological products, and aesthetic and corrective medical solutions. It offers products for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis (fungal nail infections), pigmentary disorders, and skin cancer, as well as medical aesthetic and corrective solutions for skin senescence.

Company Name	Galderma S.A.
Website	www.nestleskinhealth.com
Established Time	1981
Plants Distribution	Europe, North America, Asia-Pacific
Sales Region	Europe, North America, Asia-Pacific, South America